COVID-19相关急性肾损伤患者尿液代谢组显示NAD+生物合成受损
本研究通过病例对照设计,在两个独立住院COVID-19成人队列中采用液相色谱-质谱检测尿液代谢物。发现病例组尿液喹啉酸与色氨酸比值(Q/T)升高,提示NAD+生物合成受损,且能量与嘌呤代谢改变构成可区分AKI与否的尿液代谢特征。
要点
- COVID-19相关AKI患者尿液Q/T比值升高,提示NAD+生物合成受损。
- 尿液代谢特征可区分AKI与非AKI,随机森林分类错误率低。
- NAD+生物合成通路可能是COVID-19相关AKI的潜在治疗靶点。
核心结论
- COVID-19住院患者中,涉及多条生化通路的尿液代谢物可区分AKI与非AKI,并提示NAD+生物合成存在保守性受损。
研究设计与样本
- 病例对照研究,纳入波士顿危重症队列和伯明翰普通队列两个独立住院COVID-19成人人群;病例为KDIGO标准2或3期AKI,对照无AKI;尿液代谢物用液相色谱-质谱检测。
主要发现
- 波士顿队列纳入14例病例和14例对照,伯明翰队列纳入8例病例和10例对照。
- 两个地点病例组尿液Q/T比值均升高,合并分析中病例中位数1.34(IQR 0.59-2.96),对照0.31(IQR 0.13-1.63),P=0.0013。
- 能量代谢和嘌呤代谢改变构成区分AKI与否的尿液代谢特征,监督随机森林分类错误:波士顿28例中2例,伯明翰18例中0例。
关键数值与推荐
- AKI定义采用KDIGO标准2或3期。
临床怎么用
- 尿液Q/T比值和代谢组特征可能辅助识别COVID-19相关AKI高风险患者。
- NAD+生物合成通路受损提示靶向该通路可能成为减轻COVID-19相关AKI的新策略。
局限性
- 样本量小(波士顿28例,伯明翰18例),为病例对照设计,需更大队列验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Acute kidney injury (AKI) is common in COVID-19 and associated with increased morbidity and mortality. We investigated alterations in the urine metabolome to test the hypothesis that impaired nicotinamide adenine dinucleotide (NAD+) biosynthesis and other deficiencies in energy metabolism in the kidney, previously characterized in ischemic, toxic, and inflammatory etiologies of AKI, will be present in COVID-19-associated AKI. METHODS: This is a case-control study among the following 2 independent populations of adults hospitalized with COVID-19: a critically ill population in Boston, Massachusetts, and a general population in Birmingham, Alabama. The cases had AKI stages 2 or 3 by Kidney Disease Improving Global Outcomes (KDIGO) criteria; the controls had no AKI. Metabolites were measured by liquid chromatography-mass spectrometry. RESULTS: A total of 14 cases and 14 controls were included from Boston and 8 cases and 10 controls from Birmingham. Increased urinary quinolinate-to-tryptophan ratio (Q/T), found with impaired NAD+ biosynthesis, was present in the cases at each location and pooled across locations (median [interquartile range]: 1.34 [0.59-2.96] in cases, 0.31 [0.13-1.63] in controls, P = 0.0013). Altered energy metabolism and purine metabolism contributed to a distinct urinary metabolomic signature that differentiated patients with and without AKI (supervised random forest class error: 2 of 28 in Boston, 0 of 18 in Birmingham). CONCLUSION: Urinary metabolites spanning multiple biochemical pathways differentiate AKI versus non-AKI in patients hospitalized with COVID-19 and suggest a conserved impairment in NAD+ biosynthesis, which may present a novel therapeutic target to mitigate COVID-19-associated AKI.
引用
- Raines NH, Cheung MD, Wilson LS, et al. Nicotinamide Adenine Dinucleotide Biosynthetic Impairment and Urinary Metabolomic Alterations Observed in Hospitalized Adults With COVID-19-Related Acute Kidney Injury. Kidney Int Rep. 2021. PMID: 34541422. doi:10.1016/j.ekir.2021.09.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。